Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 17 Show results per page	View Search Criteria \| Help With Results


1.		Low-Dose Peg-Interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				25 to 75				Other				O2006-415 NCT00375661

Last Modified: 9/19/2008 First Published: 8/19/2005


2.		Phase III Randomized Study of Neoadjuvant Induction Therapy Comprising Doxorubicin, Cisplatin, and High-Dose Methotrexate (MAP) Followed by Surgery and Adjuvant Maintenance Therapy Comprising MAP Alone Versus MAP and PEG-Interferon Alfa-2b OR MAP Combined With Ifosfamide and Etoposide in Patients With Resectable High-Grade Osteosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				5 to 40 at diagnostic biopsy				NCI				COG-AOST0331 AOST0331, NCT00134030, ISRCTN67613327, EU-20530, MRC-EURAMOS1, MRC-BO08, EUDRACT-2004-000242-20


3.		Rituximab After Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				60 and over				Other				MCL2004-1 NCT00209209

Last Modified: 9/7/2008 First Published: 11/1/2002


4.		Phase II Study of Low-Dose PEG-Interferon alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				ECOG-2602 E2602, NCT00049530

Last Modified: 6/22/2007 First Published: 11/24/2002


5.		Phase II Study of PEG-Interferon alfa-2b and Thalidomide in Adults With Recurrent High Grade Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				NCI-03-C-0002 NABTC-0201, NCT00052650


6.		Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and Peginterferon Alfa-2b [PEG-INTRON(R)]

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				2006-0360 NCT00415857

Last Modified: 6/13/2008 First Published: 4/20/2007


7.		Phase II Study of Gefitinib and PEG-Interferon alfa-2b in Patients With Unresectable or Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				CCC-PHII-40 ZENECA-AZ1839US/0227, PHII-40, UCD-200412338-4, UCD-ZD1839, NCT00467077


8.		Temozolomide Alone or With PGI in Melanoma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				2005-0143 NCT00525031


9.		Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				21 and under				NCI, Other				MEL06 NCT00539591


10.		Combined Treatment of Sorafenib and Pegylated Interferon a2b in Stage IV Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				DeCOG SoraPeg 2007 EudraCT 2007-001918-16, NCT00623402

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute